152121-19-2

Basic information

• Product Name: 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole
• Synonyms: 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole
• CAS NO: 152121-19-2
• Molecular Weight: 340.359
• Mol File: 152121-19-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole(152121-19-2)
• EPA Substance Registry System: 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole(152121-19-2)

Safety Data

• Hazardous Substances Data: 152121-19-2(Hazardous Substances Data)

Upstream product

• 6576-05-2 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone 
• 116332-54-8 4-fluoro-N-methoxy-N-methylbenzamide 
• 105-07-7 4-cyanobenzaldehyde 
• 152122-41-3 2-(tert-butyldimethyl-silyloxy)-1-(4-fluorophenyl)-2-pyridin-4-yl-ethanone 
• 152121-20-5 2-(4-Cyanophenyl)-4-(4-fluorophenyl)-1-N-hydroxy-5-(4-pyridyl)imidazole 
• 403-43-0 4-fluorobenzoyl chloride 
• 108-89-4 picoline 
• 117423-41-3 4-((tert-butyldimethylsilyloxy)methyl)pyridine 

Downstream Products

• 152121-79-4 4-[4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]benzamidoxime 
• 152121-32-9 4-[4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]benzoic acid 
• 152121-34-1 2-(4-Aminomethylphenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole 

Relevant articles and documents

Triarylimidazole derivatives as cytokine inhibitors

Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are various substituent groups; and one of X1 and X2 is N or CR″, and the other is NR″ or CHR″ wherein R″

Treatment for CNS injuries

The present invention is directed to the use of 2,4,5-trisubstituted imidazole compounds and compositions in the treatment of CNS injuries to the brain.

Substituted imidazoles as glucagon receptor antagonists

A modestly active, nonselective triarylimidazole lead was optimized for binding affinity with the human glucagon receptor. This led to the identification of a 2- and/or 4-alkyl or alkyloxy substituent on the imidazole C4-aryl group as a structural determinant for significant enhancement in binding with the glucagon receptor (e.g., 41, IC50 = 0.053 μM) and selectivity (> 1000 ×) over p38 MAP kinase in this class of compounds.